Patents by Inventor Lise Giehm

Lise Giehm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210244798
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 12, 2021
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20210115104
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: August 6, 2020
    Publication date: April 22, 2021
    Applicant: Zealand Pharma A/S
    Inventors: Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Skodborg VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
  • Patent number: 10905745
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: February 2, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
  • Publication number: 20200297818
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: September 24, 2020
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • Publication number: 20200207825
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Application
    Filed: September 11, 2019
    Publication date: July 2, 2020
    Inventors: Ditte RIBER, Lise GIEHM
  • Publication number: 20200188485
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: October 25, 2019
    Publication date: June 18, 2020
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Publication number: 20190365865
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190338009
    Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: December 11, 2017
    Publication date: November 7, 2019
    Inventors: Bjarne Due LARSEN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Patent number: 10442847
    Abstract: The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 15, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • Publication number: 20190142904
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 16, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190134159
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 9, 2019
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Patent number: 10071140
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 11, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
  • Publication number: 20180071366
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: September 8, 2017
    Publication date: March 15, 2018
    Inventors: Jesper Mosolff MATHIESEN, Jesper Skodborg VILLADSEN, Lise GIEHM, Henrik Kofoed MUNCH, Dieter Wolfgang HAMPRECHT, Alexander HEIM-RIETHER, Giacomo FOSSATI
  • Publication number: 20160272693
    Abstract: The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Inventors: Rasmus JUST, Oliver DEMMER, Lise GIEHM, Jesper Sloth VILLADSEN, Henrik MUNCH, Jesper Mosolff MATHIESEN, Jolanta SKARBALIENE, Maria DERYABINA, Dieter Wolfgang HAMPRECHT
  • Publication number: 20150210744
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Application
    Filed: July 23, 2013
    Publication date: July 30, 2015
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm